Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Latest Glucagon rescue Stories

2012-06-08 10:23:20

DANBURY, Conn., June 8, 2012 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) and Aegis Therapeutics, LLC (Aegis) today announced a partnership providing Biodel an exclusive worldwide license to Aegis' proprietary ProTek® and Intravail® technologies for the development and commercialization of pharmaceutical formulations of glucagon. ProTek® protein stabilization technology comprises the use of proprietary GRAS excipients that prevent aggregation of proteins and peptides thereby...

2012-05-10 02:30:44

DANBURY, Conn., May 10, 2012 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) today reported financial results for the second fiscal quarter ended March 31, 2012. Highlights since Beginning of Second Fiscal Quarter Announced a planned New Drug Application (NDA) submission by the first calendar quarter of 2014 for a proprietary glucagon rescue formulation. Successfully completed a Phase 1 trial study of recombinant human insulin (RHI)-based ultra-rapid-acting prandial insulin formulations...

2012-03-14 15:00:00

DANBURY, Conn., March 14, 2012 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) today will provide an update on its stabilized glucagon program at the ROTH 24th Annual OC Growth Stock Conference in Laguna Niguel, California. This presentation will be webcast at 5:00 p.m. EDT (2:00 p.m. PDT). The company recently received feedback from the FDA regarding the regulatory path forward for the development of a stabilized liquid glucagon for use as a rescue treatment for severe...

2010-06-28 08:00:00

INDIANAPOLIS, June 28 /PRNewswire-FirstCall/ -- Marcadia Biotech, Inc. and Eli Lilly and Company (NYSE: LLY) today announced that the companies have signed a development and exclusive license agreement for Marcadia's short-acting glucagon program, covering glucagon analogs that may provide greater convenience and ease-of-use than the current recombinant glucagon for the treatment of severe hypoglycemia. The program includes MAR531, a glucagon analog that is in preclinical development at...

2009-11-12 02:43:00

LONDON, November 12 /PRNewswire/ -- The on-line journal Diabetic Hypoglycemia (http://www.hypodiab.com/) supports the message of World Diabetes Day 2009 (http://www.worlddiabetesday.org) in their call for greater understanding and taking control of diabetes. This year's campaign takes a three pronged approach in tackling the global diabetes epidemic. It calls on healthcare providers to gain a greater understanding of the condition and how best to manage it. It has a message of...